Holen Sie sich die Stockscreener-App
4.95
2.56%
-0.13
Handel nachbörslich:
5.00
0.05
+1.01%
Schlusskurs vom Vortag:
$5.08
Offen:
$5.08
24-Stunden-Volumen:
690.16K
Relative Volume:
0.68
Marktkapitalisierung:
$204.91M
Einnahmen:
$134.48M
Nettoeinkommen (Verlust:
$-38.94M
KGV:
-5.1919
EPS:
-0.9534
Netto-Cashflow:
$-19.34M
1W Leistung:
-11.76%
1M Leistung:
+7.61%
6M Leistung:
-44.00%
1J Leistung:
-41.49%
1-Tages-Spanne:
$4.875
$5.11
1-Wochen-Bereich:
$4.805
$5.90
52-Wochen-Spanne:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.95 | 204.91M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - Yahoo Finance
RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties - GuruFocus
RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST) - Seeking Alpha
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - The AI Journal
(RXST) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Midday Stock Roundup: Alignment Healthcare Up 7.8% Ahead of Q2 Results - Orange County Business Journal
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E? - simplywall.st
Is Alcon (SWX:ALC) Undervalued After Its RxSight Collaboration? - Yahoo Finance
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - FinancialContent
Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones? - Insider Monkey
RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST) - Seeking Alpha
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs - InvisionMag.com
Price to book forward of RxSight, Inc. – NASDAQ:RXST - TradingView
RxSight, Inc. Reports Preliminary Financial Results for the Second Quarter of 2026 - VisionMonday.com
Price to sales forward of RxSight, Inc. – NASDAQ:RXST - TradingView
Alcon and RxSight partner to to develop light-adjustable PCIOLs - Eyes On Eyecare
ALC News & Events - Intellectia AI
Enterprise value to EBIT forward of RxSight, Inc. – NASDAQ:RXST - TradingView
RxSight (RXST) Adjusts FY26 Revenue Forecast Amid Collaboration Insights - GuruFocus
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - Business Wire
RXST Maintained by B of A Securities -- Price Target Lowered to $6.50 - GuruFocus
BofA cuts RxSight stock price target on weak Q2 sales, guidance - Investing.com Nigeria
BofA cuts RxSight stock price target on weak Q2 sales, guidance By Investing.com - Investing.com South Africa
RxSight Announces Preliminary Q2 Results - Orange County Business Journal
RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities - StreetInsider
RxSight, Inc. Provides Preliminary Revenue Guidance for the Second Quarter Ended June 30, 2026 - marketscreener.com
RxSight stock tumbles on reduced 2026 sales guidance By Investing.com - Investing.com South Africa
Alcon, RxSight Begin Co-Developing Presbyopia-Correcting IOLs - Medical Product Outsourcing
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal By Investing.com - Investing.com South Africa
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal - Investing.com
Rxsight Q2 Revenue USD 27 Million Vs. IBES Es - Moomoo
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight - Yahoo Finance
RxSight reports preliminary Q2 revenue, revises 2026 guidance - MSN
RxSight (RXST) Reiterated at Hold by Stifel as ALC Collaboration Announced - StreetInsider
Rivian Automotive, Penguin Solutions And 3 Stocks To Watch Heading Into Tuesday - Benzinga
RXST: 2026 revenue guidance lowered, gross margin raised, and next-gen lens pipeline advances - TradingView
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs - VisionMonday.com
RxSight raises FY26 sales guidance to $140M-$160M - scanx.trade
Alcon, RxSight partner on adjustable lens technology - Investing.com UK
Alcon, RxSight partner on adjustable lens technology By Investing.com - Investing.com South Africa
Alcon (ALC) Partners with RxSight for Innovative Lens Developmen - GuruFocus
RxSight reports Q2 revenue of $32-34M, cuts 2026 sales outlook - Investing.com
ALCON AGRXSIGHT TO RECEIVE $60 MLN UPFRONT PAYMENT UNDER AGREEMENT - Moomoo
RxSight says Q2 results hit by more widespread competitive trialing - TradingView
RxSight cuts 2026 sales outlook, citing competitive headwinds - StreetInsider
RxSight (NASDAQ: RXST) cuts 2026 sales outlook but lifts margin view - Stock Titan
Rxsight, Inc. Updates Revenue Guidance for the Full Year 2026 - marketscreener.com
Join Class Action to Recover Losses From RxSight, Inc. (RXST)Contact Levi & Korsinsky Before September 22, 2025 - The National Law Review
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):